Related references
Note: Only part of the references are listed.CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
High-throughput identification of antigen-specific TCRs by TCR gene capture
Carsten Linnemann et al.
NATURE MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Dissection of T-cell Antigen Specificity in Human Melanoma
Rikke Sick Andersen et al.
CANCER RESEARCH (2012)
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Rikke Sick Andersen et al.
NATURE PROTOCOLS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients
Pia Kvistborg et al.
ONCOIMMUNOLOGY (2012)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Rong Rong Huang et al.
CLINICAL CANCER RESEARCH (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
CD8+ Enriched Young Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley et al.
CLINICAL CANCER RESEARCH (2010)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
Sine Reker Hadrup et al.
NATURE METHODS (2009)
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
Hong Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Begona Comin-Anduix et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Design and use of conditional MHC class I ligands
M Toebes et al.
NATURE MEDICINE (2006)
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
AV Maker et al.
JOURNAL OF IMMUNOLOGY (2005)
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
PG Coulie et al.
IMMUNOLOGICAL REVIEWS (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)